Tiziana was previously notified by Nasdaq on January 29, 2025 that it was not in compliance with the minimum bid-price listing rule (under Rule 5550 (a) (2)) because its common stock failed to meet ...

Among them, CD3 is considered to be the primary target. Image Credit: ACROBiosystems CD3 molecules tend to bind to TCR non-covalently to develop a TCR/CD3 receptor complex on the T-cell’s surface.

Rep. Jeff Hurd, the Republican representing Colorado’s 3rd Congressional District in the U.S. House of Representatives, ...

The test uses an AI algorithm to accurately assess the number of immune cells known as CD3 inside early-stage bowel cancer tumors. Bowel cancer, also known as colorectal cancer, is found anywhere ...

Ongoing Phase 1 and Phase 2 clinical programs continue to exhibit long-term durable remissions in hard-to-treat cancers, ...

In addition, the association of CD3 with the TCR–peptide–MHC complex transmits the activation signal to intracellular signalling molecules to initiate a signalling cascade in the T cell.

It contains one Ig-like (immunoglobulin-like) domain and one ITAM domain. CD3E, along with CD3-gamma, CD3-delta, CD3-zeta, and T-cell receptor (TCR) alpha/beta or gamma/delta heterodimers ...

Nasal anti-CD3 spray reduces traumatic brain injury in mice, a potential breakthrough for TBI treatment. Read now.

Shares of Tiziana Life Sciences (NASDAQ:TLSA) jumped 12% Thursday after the company said that a study of its drug candidate intranasal foralumab in the treatment of traumatic brain injury has been ...

Medigene AG (Medigene, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor ...

A new study suggests a nasal spray developed to target neuroinflammation could one day be an effective treatment for traumatic brain injury (TBI). By studying the effects of the nasal anti-CD3 in a ...

Fully human intranasal foralumab shows promise in treating Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS.